Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026)

Jushi Holdings' (JUSHF) quarterly Income from Continuing Operations came in at 19847000.0 in Q1 2026, down 16.64% year-on-year from 23809962.98 in Q1 2025, and down 27.58% on a QoQ basis from 15556000.0 in Q4 2025.

Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026) Analysis & Trends

Jushi Holdings (JUSHF) has 6 years of Income from Continuing Operations data on file, last reported at 19847000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 16.64% year-over-year to 19847000.0 in Q1 2026; TTM through Mar 2026 was 71423000.0, a 50.56% decrease from a year earlier, with the FY2025 full-year figure at 68591000.0, down 40.62% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 19847000.0, down from 15556000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for JUSHF reached as high as 12066000.0 in Q2 2022 and fell as low as 139937000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 23802411.76 across 5 years, with a median of 17015000.0 in 2025.
  • On a YoY basis, Income from Continuing Operations climbed as much as 357.74% in 2022 and fell as far as 2353.05% in 2022.
  • Year by year, Income from Continuing Operations stood at 139937000.0 in 2022, then surged by 87.13% to 18004000.0 in 2023, then surged by 30.75% to 12468000.0 in 2024, then retreated by 24.77% to 15556000.0 in 2025, then fell by 27.58% to 19847000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 19847000.0 in Q1 2026, 15556000.0 in Q4 2025, and 23689000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Jushi Holdings 81.25 Mn 41.54 Mn 29.88 Mn -19.85 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.85 Mn
Dec 31, 2025 -15.56 Mn
Sep 30, 2025 -23.69 Mn
Jun 30, 2025 -12.33 Mn
Mar 31, 2025 -17.02 Mn
Dec 31, 2024 -12.47 Mn
Sep 30, 2024 -16.02 Mn
Jun 30, 2024 -1.94 Mn
Mar 31, 2024 -18.36 Mn
Dec 31, 2023 -18.00 Mn
Sep 30, 2023 -20.62 Mn
Jun 30, 2023 -14.04 Mn
Mar 31, 2023 -12.44 Mn
Dec 31, 2022 -139.94 Mn
Sep 30, 2022 -54.70 Mn
Jun 30, 2022 12.07 Mn
Mar 31, 2022 -19.76 Mn
Dec 31, 2021 6.21 Mn
Sep 30, 2021 39.68 Mn
Jun 30, 2021 2.64 Mn